Bourgoin Jallieu

Researchers are evaluating different antimicrobial therapies for infections caused by difficult-to-treat Pseudomonas aeruginosa, a type of bacteria resistant to many common antibiotics. This study focuses on comparing new beta-lactambeta-lactamase inhibitor combinations, cefiderocol, and older treatments like aminoglycosides and colistin to understand their effectiveness in real-life settings for patients facing these challenging infections. The study is a prospective, multicenter cohort involving patients who require intravenous antibiotic treatment for their P. aeruginosa infections. Participating patients will receive one of the available antimicrobial options, and their bacterial samples will be analyzed centrally to assess susceptibility and resistance mechanisms. The study collects clinical data throughout treatment and monitors outcomes such as cure rates, resistance development, adverse events, and mortality. Participants will be followed until hospital discharge and up to 28 days after treatment completion. Researchers will track clinical cures, microbiological eradication, adverse events, emergence of resistance, and acquisition of other multidrug-resistant bacteria. Data collection includes electronic case reports and laboratory testing on bacterial isolates. The total participation duration varies according to hospital stay and follow-up schedules, with rigorous monitoring of safety and treatment outcomes.

Primary Sjf6grens syndrome pSS is a chronic autoimmune disease that affects multiple organs and leads to decreased quality of life. The condition often has periods of flares and relapses, making reliable biomarkers important for tracking disease activity. Researchers are studying the presence of anti-RoSSA IgE antibodies as a potential biomarker to better determine pSS activity, given their role in autoimmune responses and interferon alpha signaling. Participants with primary Sjf6grens syndrome will have blood samples taken to measure anti-RoSSA IgE levels using an ELISA test. This observational study includes patients diagnosed according to the American-European Consensus Criteria. The study focuses on comparing antibody presence with disease activity and other clinical features. During the study, participants will provide blood samples at the start to assess antibody levels. Researchers will collect data on disease activity using the Eular Sjf6gren Syndrome Disease Activity Index and related symptom scores. The study will explore correlations between antibody presence and disease features, including lymphoma onset and interferon alpha signature, with some outcomes reviewed over five years.

Colorectal cancer CRC is a common cancer worldwide, with an increasing incidence, especially in developing countries. A serious complication after colorectal surgery for left-sided or high rectal cancer is anastomotic leakage AL, which can lead to death, longer hospital stays, worsened quality of life, and higher medical costs. This trial evaluates whether using intraoperative fluorescence angiography IOFA with indocyanine green ICG during surgery can reduce the rate of AL compared to standard surgery without IOFA. In this phase III, national, multicenter, single-blind randomized trial, adult patients scheduled for elective left colectomy or high rectal resection with intraperitoneal anastomosis are assigned to one of two groups. The experimental group receives surgery with IOFA where ICG is injected intravenously to assess blood flow in the colon before performing the anastomosis. The control group undergoes surgery without the use of IOFA. The study includes 1010 patients across 26 centers, with follow-up visits up to 90 days after surgery. Participants are involved in three main visits a pre-operation visit for screening and consent, surgery with or without IOFA, and follow-up visits at 30 and 90 days post-operation. Researchers collect clinical data, quality of life questionnaires, and monitor for AL occurrence. The primary outcome is the rate of AL within 90 days after surgery. Secondary outcomes include changes in surgical plans, stoma rates, complications, mortality, hospital stay length, reinterventions, and cost analysis. Patient safety and health are carefully monitored throughout the study period.

Researchers are studying lymphoma in adults to better understand prognostic factors by combining epidemiological, clinical, and biological data. The study focuses on seven subtypes of lymphoma and aims to identify causes of treatment resistance and relapse, monitor long-term health effects, and assess quality of life and second cancers in survivors. This observational platform also looks at how treatments work in real life and explores socio-economic issues related to lymphoma. Participants diagnosed with lymphoma within the last six months and who consent to join the REALYSA cohort provide data for this study. There is no treatment given as part of this observational study instead, data about the patients lymphoma subtype, treatments received, and outcomes are collected and analyzed over time. Patients are included from various regions and lymphoma subtypes to create a comprehensive database. During the study, researchers collect ongoing information about patients health, treatments, and disease progression. They measure outcomes such as progression-free survival over five years and record events like second cancers and chronic diseases. The study tracks patients response rates, survival, and frequency of lymphoma transformations. Participants are followed long-term to better understand lymphoma outcomes and quality of life.

Researchers are studying the relationship between how the body processes venetoclax pharmacokinetics and how the drug affects patients pharmacodynamics with Acute Myeloid Leukemia AML. This prospective, multicenter clinical-biological cohort study aims to better understand venetoclaxs effects in patients starting treatment for AML. The study involves minimal risks related to blood sample collection and does not change participants therapeutic management. The study includes blood samples taken for pharmacokinetic dosing of venetoclax at different points during the treatment period. Up to 21 samples may be collected, with a maximum of 12 mL of blood per sampling day. Patients included will be those starting venetoclax-azacitidine as first-line treatment, with no triple targeted therapy combinations allowed. Participants will provide blood samples for pharmacokinetic testing and clinical data collection from the first day of venetoclax administration through treatment and follow-up periods. Researchers will measure the best pharmacokinetic indicators of treatment response and assess the relationship between venetoclax exposure and clinical outcomes or adverse events. The study plans follow-up for at least 24 months to observe variability in drug exposure and effects.

This research aims to collect detailed information about hypoparathyroidism in France, a condition with few epidemiological studies worldwide and none specific to France. The study focuses on understanding the frequency of this condition, the medications used, and the complications it may cause, such as low calcium symptoms, calcifications in the brain and tissues, kidney stones, and kidney problems. Participants will not receive any treatment as part of this study since it is observational. The study gathers data from patients diagnosed with chronic hypoparathyroidism living in France to assess their medical history, current treatments, and any complications related to their condition. There is no intervention or drug administration involved. During the study, researchers will review participants biological data including calcium, urine calcium, parathormone, creatinine, phosphate, and magnesium levels at diagnosis and during treatment. They will also collect information about patient management and complications. This data collection will continue for about two years, helping to understand the conditions progression and treatment outcomes in the French population.